Should it be approved, BioMarin is considering pricing Valrox, a gene therapy drug aimed at hemophilia A, at $2 million to $3 million for the single treatment.
Read moreZolgensma and Gene Therapy: What is the Cost?
Gene therapy in healthcare has become a reality, and it is set to move from a trickle to a stream in the next few years. This article discusses Zolgensma and other emerging gene therapies in the context of how they may affect a health plan’s costs.
Read moreNew Specialty Pharmacy Program for Summit Re Clients
Summit Reinsurance Services, Inc. today announced a strategic collaboration with RxResults, a pharmacy risk manager. Through this collaboration, Summit Re clients will have access to proprietary informatics, clinical expertise, and business processes to help formulate actionable insights and implement evidence-based strategic initiatives in order to manage pharmacy and specialty pharmacy spend.
Read more